Login to Your Account



Avastin Letter Nips Shares But Genentech In Recovery

By Randall Osborne


Tuesday, August 17, 2004
Genentech Inc.'s stock was nicked more than 6 percent Friday by news of a "dear doctor" letter regarding the colorectal cancer drug Avastin, but on Monday showed signs of rebounding from concern that William Tanner, analyst with Leerink Swann & Co. in New York, called "overblown." (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription